News about Global Pharma

Strides Pharma Gets Recognition in S&P Global Sustainability Yearbook 2025

This recognition reflects Strides progress in integrating ESG principles across its operations.

Global Pharma | 02/04/2025 | By Aishwarya |  492

Gennova Collaborates with CEPI to Advances AI-Enhanced saRNA Vaccine for Nipah Virus

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, partners with Coalition for Epidemic Preparedness Innovations (CEPI) and Houston Methodist to develop an AI-enhanced saRNA vaccine for the deadly Nipah virus, securing up to USD 13.38 million for accelerated research and trials in India.

Global Pharma | 01/04/2025 | By Manvi |  390

Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment

Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.

Global Pharma | 01/04/2025 | By Abha |  509

Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer

Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as Chief Executive Officer. Dr. Bolen most recently served as Orna's Chief Scientific Officer (CSO) and succeeds Amit Munshi who is stepping aside for personal reasons.

Global Pharma | 31/03/2025 | By Manvi |  178

SPARC Submits IND Application for SBO-154 to USFDA

Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.

Global Pharma | 31/03/2025 | By Aishwarya |  349

Spyre Therapeutics Initiates Dosing of First Participant in Phase 1 Trial of SPY003

The SPY003 Phase 1 Trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study in healthy volunteers.

Global Pharma | 31/03/2025 | By Aishwarya |  340

IASO Bio Gets Approval of New Drug Application for Equecabtagene Autoleucel

Equecabtagene Autoleucel (FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent.

Global Pharma | 31/03/2025 | By Aishwarya |  237

Suven Pharmaceuticals Secures NCLT Approval for Merger with Cohance Lifesciences

Over 99.9994 percent of Suven’s equity shareholders and 99.967 percent of Cohance’s shareholders voted in favor of the Scheme of Amalgamation during meetings held on November 28, 2024.

Global Pharma | 31/03/2025 | By Aishwarya |  712

Visby Medical Receives FDA De Novo Authorization for OTC Women's Sexual Health Test

Visby Medical announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for the Visby Medical Women's Sexual Health Test for Over the Counter (OTC) use. This groundbreaking test enables reliable, rapid, and private at-home testing for Chlamydia, Gonorrhea, and Trichomoniasis—the three most common curable STIs.

Global Pharma | 29/03/2025 | By Manvi |  243

FDA Approves Novel Treatment for Hemophilia A or B

The FDA has approved Qfitlia (fitusiran) for routine prophylaxis in hemophilia A and B patients aged 12 and older, offering a less frequent dosing option by targeting antithrombin to enhance clotting and reduce bleeding episodes.

Global Pharma | 29/03/2025 | By Manvi |  250